Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on therapies for RAS-addicted cancers, will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference from June 13-16, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on therapies for RAS-addicted cancers, will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference from June 13-16, 2022. CEO Mark A. Goldsmith will host a live fireside chat on June 15, 2022, at 1:20 p.m. Pacific Time. Investors can access the live webcast at here, with an archived replay available for 14 days post-event.
Details
News Market Reaction – RVMD
The recorded move for RVMD in the trading session of this news was -5.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event.
Details of the company’s participation are as follows:
- Conference Date: June 13 – 16, 2022
- Fireside Chat Details: 1:20 p.m. Pacific on Wednesday, June 15, 2022
A live webcast of the fireside chat can be accessed at: https://ir.revmed.com/events-and-presentations. An archived replay of the webcast will be available on the investors section of the company’s website for at least 14 days following the event.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RASMULTI), RMC-6291(KRASG12C), RMC-9805 (KRASG12D) and RMC-8839 (KRASG13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.